<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210324</url>
  </required_header>
  <id_info>
    <org_study_id>ZZYY-MF-10-401</org_study_id>
    <nct_id>NCT03210324</nct_id>
  </id_info>
  <brief_title>A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy</brief_title>
  <official_title>Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Resources Zizhu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Resources Zizhu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and adverse effects of mifepristone tablets in widely used
      conditions, to evaluate the relationship between interests and risks used in general or
      special populations, to further observe the safety and efficacy of drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine fibroids (also referred to as myomas, leiomyomas, leiomyomata, and fibromyomas) are
      non-cancerous (benign) tumors that grow within the muscle tissue of the uterus. Approximately
      20-40% of women 35 years and older have fibroids. While many women with fibroids do not
      experience any symptoms, the location and size of fibroids can cause symptoms that can affect
      a woman's quality of life.

      Fibroids are hormonally sensitive so symptoms are likely to be cyclical with menstruation.
      Fibroid growth is dependent on hormone levels; an increase in a woman's hormone levels may
      cause the size of fibroids to increase. During menopause, these hormones decrease
      dramatically and may cause fibroid symptoms to diminish.

      Mifepristone is an antiestrogen hormone that antagonizes progesterone at receptor levels.
      Estrogen is generally considered to be a major contributor to uterine fibroids, but many
      studies have confirmed that progesterone can promote fibroid cell mitosis, and thus promote
      fibroids growth. In recent years, domestic and international clinical studies have shown that
      mifepristone treatment for 3 months can significantly reduce the size of uterine fibroids to
      achieve complete amenorrhea, improve bleeding caused by anemia, reduce clinical symptoms,
      uterine fibroids to reduce the size of complex Of the hysterectomy surgery into a simple, to
      avoid surgery caused by other organs of the injury, shorten the operation time, reduce the
      amount of surgical bleeding and blood transfusion, so that patients recover faster after
      surgery The literature reported the clinical use of 50mg, 25mg, 10mg and 5mg. The minimum
      dose of 10mg daily, 3 months can reduce the average size of uterine fibroids nearly half.
      Daily 5mg on fibroids shrink is not obvious. Mifepristone tablets is developed by the China
      Resources Zizhu Pharmaceutical Co., Ltd. Drugs and Drugs 1.6, each tablet 10mg, for adult age
      women have moderate to severe symptoms of uterine fibroids before the treatment of national
      food and drug supervision and management General Administration of the People 's Republic of
      China on October 24, 2014 approved its listing, the drug registration approval number:
      2014S00506. According to the State Food and Drug Administration drug clinical approval
      requirements of this product need to carry out IV clinical research, the purpose is to
      examine the efficacy of drugs in a wide range of conditions and adverse reactions to evaluate
      the general or special population in the use of the interests and risks , To further observe
      the safety and efficacy of drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Security assessments</measure>
    <time_frame>Up to study completion at approximately 24 weeks</time_frame>
    <description>Security assessments will include monitoring and recording all adverse events (AEs) and serious adverse events (SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of uterine fibroids(maximal fibroids)</measure>
    <time_frame>Through study completion，an average of half year</time_frame>
    <description>Comparison of changes in the volume group of uterine fibroids (maximal fibroids)before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in the uterine volume</measure>
    <time_frame>Through study completion，an average of half year</time_frame>
    <description>Comparison of changes in the uterine volume before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the relevant indicators of anemia</measure>
    <time_frame>Through study completion，an average of half year</time_frame>
    <description>Before and after treatment on the relevant indicators of anemia(red blood cell count, erythrocyte ratio, hemoglobin) groups of visits to the relative baseline changes in the value of the description, the group comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the uterine bleeding symptoms</measure>
    <time_frame>Through study completion，an average of three months</time_frame>
    <description>The uterine bleeding symptoms were recorded before treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation situation(Perioperative transfusion improvement,Type of surgery)</measure>
    <time_frame>Through study completion，an average of half year</time_frame>
    <description>When surgery was occurred, recording perioperative blood transfusion values; if the operation was performed, the proportion of subjects using minimally invasive surgery was calculated for all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptom scores</measure>
    <time_frame>Through study completion，an average of half year</time_frame>
    <description>The clinical symptom scores were recorded before treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Uterine Fibroid</condition>
  <arm_group>
    <arm_group_label>Mifepristone A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone tablets for 12 weeks with two follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone tablets for 12 weeks with four follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone C group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone tablets for 24 weeks with four follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone tablets</intervention_name>
    <description>Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.</description>
    <arm_group_label>Mifepristone A group</arm_group_label>
    <arm_group_label>Mifepristone B group</arm_group_label>
    <arm_group_label>Mifepristone C group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In line with the diagnosis of uterine fibroids;

          -  With fibroids associated with clinical symptoms (such as uterine bleeding symptoms,
             symptoms of oppression, pain symptoms, etc.); or nearly 3 months fibroids gradually
             grow; or the largest fibroid diameter ≥ 5cm;

          -  Women of childbearing age over 18 years of age;

          -  Voluntarily tested and signed informed consent

        Exclusion Criteria:

          -  Unexplained or vaginal bleeding other than uterine fibroids;

          -  Combined with malignant tumors (including reproductive and other systems), or
             endometrial ≥ 17mm;

          -  Is the use of simple progesterone contraceptives, progesterone-containing intrauterine
             device or compound oral contraceptives;

          -  Is using ketoconazole, itraconazole, erythromycin, rifampicin, adrenocorticotropic
             hormone (hydrocortisone, prednisone, dexamethasone, etc.), and some anticonvulsants
             (phenytoin, Phenobarbital, carbamazepine), griseofulvin, nonsteroidal antiinflammatory
             drugs (aspirin, acetaminophen, ibuprofen, etc.) and can not be discontinued during the
             study;

          -  Pregnant women and lactating women and medication or medication within 3 months after
             the cessation of births;

          -  Severe heart, liver, kidney disease and adrenal insufficiency, and / or ALT, AST&gt; 1.5
             times the upper limit of normal, Cr&gt; normal upper limit;

          -  Allergies or previous allergy to a variety of drugs, or the study of active
             ingredients in the medication or any excipient allergy;

          -  Patients who have participated in other clinical trials within 3 months;

          -  Other investigators who are not considered to be involved in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingfang Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Univesitay First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingfang Zhou, M.D.</last_name>
    <phone>(+86)13501238853</phone>
    <email>zhouyf8853@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Maternal and Child Health Care Hospiatl of Capital Medical Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Duan, M.D.</last_name>
      <phone>(+86)13501019066</phone>
      <email>fkwch_duan@163.com</email>
    </contact>
    <investigator>
      <last_name>Hua Duan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingfang Zhou, M.D.</last_name>
      <phone>(+86)13501238853</phone>
      <email>zhouyf8853@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuling Center Hospital of Chongqing City</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingrong Wu, M.D.</last_name>
      <phone>(+86)13330371188</phone>
      <email>flyyqrwu1188@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingrong Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Chongqing Medical Universit</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lina Hu, M.D.</last_name>
      <phone>(+86)13983930077</phone>
      <email>cqhulina@126.com</email>
    </contact>
    <investigator>
      <last_name>Lina Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Logyan</name>
      <address>
        <city>Longyan</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenrong Huang, M.D.</last_name>
      <phone>(+86)13859590100</phone>
      <email>Lyeyhwr@163.com</email>
    </contact>
    <investigator>
      <last_name>Wenrong Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ailu Li, M.D.</last_name>
      <phone>（+86)13568092122</phone>
    </contact>
    <investigator>
      <last_name>Ailu Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Hospital for Maternal amd Child Health Care</name>
      <address>
        <city>Guangdong</city>
        <state>Guandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiping Luo, M.D.</last_name>
      <phone>(+86)18620287306</phone>
      <email>2488692399@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affillated Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suiqun Guo, M.D.</last_name>
      <phone>(+86)13711673333</phone>
      <email>gsq2005@126.com</email>
    </contact>
    <investigator>
      <last_name>Suiqun Guo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fouth Hospital of Shijiazhuang</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fenglou Bai, M.D.</last_name>
      <phone>(+86)13930139355</phone>
    </contact>
    <investigator>
      <last_name>Fenglou Bai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical Universty</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peiling Li, M.D.</last_name>
      <phone>(+86)13359993791</phone>
      <email>yy88777067@163.com</email>
    </contact>
    <investigator>
      <last_name>Peiling Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huaihe Hospital of Henan University</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Tian, M.D.</last_name>
      <phone>(+86)13837856131</phone>
      <email>547003476@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jun Tian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affillated Hoapital of Zhenghzou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wuliang Wang, M.D.</last_name>
      <phone>(+86)13938406398</phone>
      <email>wangwuliang888@sina.com</email>
    </contact>
    <investigator>
      <last_name>Wuliang Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong Universty of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shixuan Wang, M.D.</last_name>
      <phone>(+86)13995553319</phone>
    </contact>
    <investigator>
      <last_name>Shixuan Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changsha Hospital for Maternal amd Child Health Care</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanfei Zhou, M.D.</last_name>
      <phone>(+86)13017391810</phone>
      <email>291808975@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yanfei Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Maternal and Child Health Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufeng Cheng, M.D.</last_name>
      <phone>(+86)13970862678</phone>
      <email>chengyf13970862678@163.com</email>
    </contact>
    <investigator>
      <last_name>Yufeng Cheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fang Chen, M.D.</last_name>
      <phone>(+86)13863631956</phone>
      <email>chenfangwf@126.com</email>
    </contact>
    <investigator>
      <last_name>Fang Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital of Fudan Universty</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Long Sui, M.D.</last_name>
      <phone>(+86)13801788118</phone>
      <email>suilong@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Long Sui, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai TCM-INTEGATED Hospital,Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ting Lai, M.D.</last_name>
      <phone>(+86)13701693460</phone>
      <email>laiting21@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ting Lai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westnorth Matertal and Child Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yali Yu, M.D.</last_name>
      <phone>(+86)13186127953</phone>
      <email>23150824a@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yali Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yanan University Affillated Hospital</name>
      <address>
        <city>Yanan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chengying Gao, M.D.</last_name>
      <phone>(+86)15091110333</phone>
      <email>15091110333@163.com</email>
    </contact>
    <investigator>
      <last_name>Chengying Gao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chendu Third Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuanhua Cai, M.D.</last_name>
      <phone>(+86)13882156212</phone>
      <email>545764207@qq.com</email>
    </contact>
    <investigator>
      <last_name>Chuanhua Cai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chengdu Women and Chirdren's Central Hosptal</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Zhang, M.D.</last_name>
      <phone>(+86)18628010538</phone>
      <email>18628010538@163.com</email>
    </contact>
    <investigator>
      <last_name>Ling Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mianyan Central Hospital</name>
      <address>
        <city>Mianyang</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Zhang, M.D.</last_name>
      <phone>(+86)13808110138</phone>
      <email>zhangyong1215@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yibin</name>
      <address>
        <city>Yibin</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiyi Wang, M.D.</last_name>
      <phone>(+86)13568092122</phone>
    </contact>
    <investigator>
      <last_name>Zhiyi Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Central Hoapital of Gynecology Obstetrics</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yinjun Zhu, M.D.</last_name>
      <phone>(+86)18920196032</phone>
      <email>zhuyj8072@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yinjun Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Hospital of Zhejiang Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinmei Zhang, M.D.</last_name>
      <phone>(+86)18957110072</phone>
      <email>zxm20130729@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinmei Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Libo Zhu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril. 2013 Dec;100(6):1722-6.e1-10. doi: 10.1016/j.fertnstert.2013.08.039. Epub 2013 Oct 2.</citation>
    <PMID>24094421</PMID>
  </reference>
  <reference>
    <citation>Wang H, Jin J. [Effects of mifepristone on estrogen and progestin receptors in human uterine leiomyoma]. Zhonghua Fu Chan Ke Za Zhi. 2000 Feb;35(2):79-81. Chinese.</citation>
    <PMID>11809103</PMID>
  </reference>
  <reference>
    <citation>Yang Y, Zheng S, Li K. [Treatment of uterine leiomyoma by two different doses of mifepristone]. Zhonghua Fu Chan Ke Za Zhi. 1996 Oct;31(10):624-6. Chinese.</citation>
    <PMID>9275461</PMID>
  </reference>
  <reference>
    <citation>Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003 Feb;101(2):243-50.</citation>
    <PMID>12576246</PMID>
  </reference>
  <reference>
    <citation>Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005 May-Jun;12(3):227-33.</citation>
    <PMID>15922980</PMID>
  </reference>
  <reference>
    <citation>Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, Thulkar J. Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India. Indian J Med Res. 2013 Jun;137(6):1154-62.</citation>
    <PMID>23852296</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mifepristone antiprogestins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

